Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01181804
First received: August 12, 2010
Last updated: September 6, 2013
Last verified: September 2013
  Purpose

This is a single-dose, randomized, cross-sectional comparison study examining the relative safety and resulting blood level profiles after administration of a new boceprevir tablet formulation versus its current capsule formulation for treatment of chronic hepatitis C. In Part 1 of the study participants will receive boceprevir tablets and capsules under fed conditions. In Part 2 of the study a new group of participants will receive boceprevir tablets and capsules under fasted conditions.


Condition Intervention Phase
Hepatitis C
Drug: boceprevir
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Definitive Bioequivalence Study of a New Boceprevir (SCH 503034) Tablet Formulation Compared to the Current Capsule Form in Healthy Male and Female Subjects.

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.

  • Maximum Plasma Concentration (Cmax) of Boceprevir Tablets Versus Capsules in Fed State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve.

  • AUCtf for Boceprevir Tablets Versus Capsules in Fasted State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.

  • Cmax of Boceprevir Tablets Versus Capsules in Fasted State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve.

  • AUC From Hour 0 to Infinity (AUCinf) in Fed State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.

  • AUCinf in Fasted State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.

  • Half Life (t1/2) of Boceprevir in Fed State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    T1/2 is the time required for a given drug concentration to decrease by 50%.

  • t1/2 Boceprevir in Fasted State [ Time Frame: Predose through 72 hours post-dose ] [ Designated as safety issue: No ]
    T1/2 is the time required for a given drug concentration to decrease by 50%.


Enrollment: 177
Study Start Date: June 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Boceprevir Tablets then Capsules (fed)
Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Name: SCH 503034
Experimental: Boceprevir Capsules then tablets (fed)
Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Name: SCH 503034
Experimental: Boceprevir Tablets then Capsules (fasted)
Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Name: SCH 503034
Experimental: Boceprevir Capsules then Tablets (fasted)
Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Name: SCH 503034

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must be willing to give written informed consent for the trial and able to adhere to dose and visit schedules.
  • Subjects must be willing to give written informed consent for pharmacogenetic

testing, and able to adhere to applicable visit schedules.

- Subjects of either gender and of any race between the ages of 18 and 65

years, inclusive, having a Body Mass Index (BMI) between 18 and 32,

inclusive. BMI = weight (kg)/height (m)^2. (Individuals with values outside (or

indicate lower or higher) of these ranges may be enrolled if clinically

acceptable to the investigator and sponsor.)

  • Subjects' clinical laboratory tests (complete blood count [CBC], blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to the investigator and within an allowed expanded range supplied by sponsor. However, subject's liver function test results (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT]) must not be elevated above normal limits at Screening and on Day -1. No rescreening of liver function tests will be allowed.
  • Subjects must be free of any clinically significant disease that would interfere with the study evaluations.
  • The Screening 12 lead electrocardiogram [ECG] conduction intervals must be within gender specific normal range (e.g, ECG QTcB,measure in males ≤430 msec and QTcB measure in females ≤450 msec, PR interval ≤200 msec).
  • Vital sign measurements (taken after ~3 minutes in a sitting position) must be

within the following ranges: (Individuals with values outside of these ranges

may be enrolled if clinically acceptable to the investigator and sponsor.)

  1. oral body temperature, between 35.0°C and 37.5°C
  2. systolic blood pressure, 90 to 140 mm Hg
  3. diastolic blood pressure, 45 to 90 mm Hg
  4. pulse rate, 40 to 100 bpm

    • Female subjects must be:
  1. postmenopausal (defined as 12 months with no menses, age > 40

    years and with a follicle-stimulating hormone [FSH] level of >40 u/mL, and serum E2 < 73 pmol/L), or

  2. surgically sterilized at least 3 months prior to baseline (eg, documented

    hysterectomy or tubal ligation), or

  3. premenopausal and if unsterilized must have used a medically

    accepted method of contraception for 3 months (or abstained from

    sexual intercourse) prior to the screening period, and agree to use a

    medically accepted method of contraception during the trial (including

    the screening period prior to receiving trial medication) and for

    2 months after stopping the trial medication. An acceptable method of

    contraception includes one of the following:

i. stable oral, transdermal, injectable, or sustained-release vaginal

hormonal contraceptive regimen without breakthrough uterine

bleeding for 3 months prior to Screening; in addition, during

study use of condom and/or spermicide (when marketed in the

country).

ii. intrauterine device (inserted at least 2 months prior to Screening

visit); in addition, during study use of condom and/or spermicide

(when marketed in the country).

iii. condom (male or female) with spermicide (when marketed

within the country),

iv. diaphragm or cervical cap with spermicide (when marketed

within the country) and condom (male),

- Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual intercourse, during the trial and for 1 month after stopping the medication.

Exclusion Criteria:

  • Female subjects who are pregnant, intend to become pregnant (within

    3 months of ending the study), or are breastfeeding.

  • Subjects who, in the opinion of the investigator, will not be able to participate optimally in the study.
  • Any surgical or medical condition which might significantly alter the

absorption, distribution, metabolism or excretion of any drug. The investigator

should be guided by evidence of any of the following, and be discussed with

the sponsor prior to enrollment into the trial:

  1. history or presence of inflammatory bowel disease, ulcers,

    gastrointestinal or rectal bleeding;

  2. history of major gastrointestinal tract surgery such as gastrectomy,

    gastroenterostomy, or bowel resection;

  3. history of pancreatic injury or pancreatitis;
  4. history or presence of liver disease or liver injury;
  5. history or presence of impaired renal function as indicated by clinically

    significant elevation in creatinine, blood urea nitrogen [BUN]/urea, urinary albumin, or

    clinically significant urinary cellular constituents ; or

  6. history of urinary obstruction or difficulty in voiding.

    - Subject who has a history of any infectious disease within 4 weeks prior to

    drug administration that in the opinion of the investigator, affects the subject's ability to participate in the trial.

    • Subjects who are positive for hepatitis B surface antigen, hepatitis C

    antibodies or human immunodeficiency virus [HIV].

    - Subjects who have a positive screen for drugs with a high potential for abuse

    (during the Screening period or clinical conduct of the trial).

    - Subjects with a history of psychiatric or personality disorders that in the

    opinion of the investigator and sponsor, affects the subject's ability to

    participate in the trial.

    - Subjects with a history of alcohol or drug abuse in the past 2 years.- Subjects who have donated blood in the past 60 days.

    - Subjects who have previously received boceprevir.

    • Subjects who are currently participating in another clinical study or have

    participated in a clinical study (e.g., laboratory or clinical evaluation) within 30 days of baseline.

    - Subjects who are part of the study staff personnel or family members of the

    study staff personnel.

    • Subjects who have demonstrated allergic reactions (eg, food, drug, atopic

    reactions or asthmatic episodes) which, in the opinion of the investigator and

    sponsor, interfere with their ability to participate in the trial.

    - Subjects who smoke more than 10 cigarettes or equivalent tobacco use per

    day.

    • Subjects who have a history of malignancy.
    • Subjects who have received any prohibited treatment (prescription and non prescription medication except acetaminophen, potent inhibitors and inducers of cytochrome P3A [CYP3A4], or vitamins and herbals) more recently than the indicated washout period prior to Randomization which, in the opinion of the investigator and sponsor, interferes with their ability to participate in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01181804     History of Changes
Other Study ID Numbers: P06992
Study First Received: August 12, 2010
Results First Received: March 23, 2012
Last Updated: September 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
boceprevir
hepatitis C
bioequivalence
SCH 503034

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on September 22, 2014